Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Cyclic nucleotide-dependent relaxation in human umbilical vessels.

Provitera L, Cavallaro G, Griggio A, Raffaeli G, Amodeo I, Gulden S, Lattuada D, Ercoli G, Lonati C, Tomaselli A, Mosca F, Villamor E.

J Physiol Pharmacol. 2019 Aug;70(4). doi: 10.26402/jpp.2019.4.13. Epub 2019 Nov 15.

2.

Vasomotor effects of hydrogen sulfide in human umbilical vessels.

Mohammed R, Provitera L, Cavallaro G, Lattuada D, Ercoli G, Mosca F, Villamor E.

J Physiol Pharmacol. 2017 Oct;68(5):737-747.

3.

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

Alfano L, Guida T, Provitera L, Vecchio G, Billaud M, Santoro M, Carlomagno F.

J Clin Endocrinol Metab. 2010 Jul;95(7):3552-7. doi: 10.1210/jc.2009-2315. Epub 2010 May 5.

PMID:
20444924
4.

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

Carlomagno F, Guida T, Anaganti S, Provitera L, Kjaer S, McDonald NQ, Ryan AJ, Santoro M.

Endocr Relat Cancer. 2009 Mar;16(1):233-41. doi: 10.1677/ERC-08-0213. Epub 2008 Nov 24.

PMID:
19029224
5.

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.

Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

6.

Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.

Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. Epub 2005 May 17.

PMID:
15899946

Supplemental Content

Loading ...
Support Center